129
Views
18
CrossRef citations to date
0
Altmetric
Case Report

Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report

, , , , , , , , , , , , ORCID Icon & show all
Pages 3295-3300 | Published online: 28 Sep 2020

References

  • Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China – key questions for impact assessment. N Engl J Med. 2020;382:692–694. doi:10.1056/NEJMp200092931978293
  • Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-531986264
  • Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi:10.1016/S0140-6736(20)30251-832007145
  • Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–460. doi:10.1007/s11427-020-1637-532009228
  • Zhang Q, Lu S, Li T, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. CR. 2019;38:173. doi:10.1186/s13046-019-1156-531023337
  • Wilson JG, K D L, Zhuo H, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a Phase 1 clinical trial. Lancet Respiratory Med. 2015;3:24–32. doi:10.1016/S2213-2600(14)70291-7
  • Connick P, Kolappan M, Crawley C, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150–156. doi:10.1016/S1474-4422(11)70305-222236384
  • Hashmi S, Ahmed M, Murad MH, et al. Survival after mesenchymal stromal cell therapy in steroid-refractory acute graft-versus-host disease: systematic review and meta-analysis. Lancet Haematol. 2016;3:e4552. doi:10.1016/S2352-3026(15)00224-0
  • Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. Cell Stem Cell. 2013;13:392–402. doi:10.1016/j.stem.2013.09.00624094322
  • Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther. 2011;9:807–822. doi:10.1586/eri.11.5621810053
  • Muraca M, Pessina A, Pozzobon M, et al. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? Published online ahead of print, 2020 Jul 3. J Control Release. 2020;325:135–140. doi:10.1016/j.jconrel.2020.06.03632622963
  • Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells. 2020;9(4):924. doi:10.3390/cells9040924
  • Bari E, Ferrarotti I, Torre ML, Corsico AG, Perteghella S. Mesenchymal stem/stromal cell secretome for lung regeneration: the long way through “pharmaceuticalization” for the best formulation. J Control Release. 2019;309:11–24. doi:10.1016/j.jconrel.2019.07.02231326462
  • Esposito M, Lucariello A, Costanzo C, et al. Differentiation of human umbilical cord-derived mesenchymal stem cells, WJ-MSCs, into chondrogenic cells in the presence of pulsed electromagnetic fields. In Vivo (Brooklyn). 2013;27:495–500.
  • Shu Y, Yang C, Ji X, et al. Reversibly immortalized human umbilical cord-derived mesenchymal stem cells (UC-MSCs) are responsive to BMP9-induced osteogenic and adipogenic differentiation. J Cell Biochem. 2018;119:8872–8886. doi:10.1002/jcb.2714030076626